Aardvark Therapeutics is a biotechnology company striving to develop treatments for metabolic and inflammatory diseases. Specifically, the company focuses on novel small molecule therapeutics that are intended to help activate the gut-to-brain signaling pathways related to hunger and appetite suppression. Aardvark Therapeutics was founded in 2017 by Andreas Niethammer and Tien Lee and is headquartered in San Diego, CA. The company’s main product candidate ARD-101 is an oral compound that aims to act as a bitter taste receptor with the goal of reducing appetite and promoting weight loss.

Register for Details

For more details on financing and valuation for Aardvark Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Aardvark Therapeutics

Forge green plus iconForge green minus icon

What is Aardvark Therapeutics's IPO price?

The IPO price for Aardvark Therapeutics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Aardvark Therapeutics?

Aardvark Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Aardvark Therapeutics shares pre-IPO?

If you own Aardvark Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Aardvark Therapeutics a publicly traded company?

Aardvark Therapeutics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

When was Aardvark Therapeutics founded?

Aardvark Therapeutics was founded in 2017.

Who are Aardvark Therapeutics's major investors?

Vickers Venture Partners
Decheng Capital
Cormorant Asset Management
Gershon Capital
Laurion Capital Management LP
Walleye Capital
SymBiosis Capital Management
Surveyor Capital
LG Technology Ventures
Cantor Fitzgerald
Prader-Willi Syndrome Association
SilverArc Capital Management
Tetragon Financial Group
Sorrento Therapeutics
BNH Investment
Premier Partners
Updated on: May 25, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.